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Abstract
The chemokine receptor 5 (CCR5) serves as a co-receptor for the human immuno-
deficiency virus-1 (HIV-1) that facilitates viral entry into cells. Individuals who are 
homozygous for a 32 bp deletion of the CCR5 gene are resistant to infection, while for 
heterozygote carriers their HIV disease progression is delayed. To understand the vari-
able HIV-1 disease course that still exists among rare carriers of this deletion, studies 
have focused on polymorphisms of the CCR5 gene. Nine different CCR5 human haplo-
types (HH) were defined as HHA, HHB, HHC, HHD, HHE, (HHF*1 and HHF*2), and 
(HHG*1 and HHG*2). Less is known about the effect of these polymorphisms during 
combined antiretroviral treatment (cART) as the influence of the CCR5 haplotypes on 
the treatment outcome was not studied extensively. We have reported four novel indels 
and two new polymorphisms from one ethnic adult Omani population in the 5′UTR of 
the CCR5 gene. Genetic diversity of the CCR5 haplotypes among acquired immunodefi-
ciency syndrome (AIDS) patients receiving cART and healthy people is discussed. Our 
results demonstrated the importance of genetic diversity in the CCR5 gene and clearly 
indicate the importance of understanding the pattern of genetic diversity and its implica-
tions for better understanding AIDS.
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1. Introduction
Human immunodeficiency virus (HIV) is the virus that causes acquired immunodeficiency 
syndrome (AIDS) [1]. Two types of HIV exist: HIV-1 which is the most common virus 
worldwide and HIV-2 that is less common and mainly restricted to East Africa. HIV targets 
and destructs the CD4+ T-helper helper cells, one of the most important cells of the immune 
system. AIDS is a major global health emergency. Not all individuals infected with HIV-1 will 
progress at the same rate toward the terminal stages of the disease. It is well known that HIV-
1-infected patients on combined antiretroviral therapy (cART) do not respond equally to treat-
ment, despite proper compliance to therapy.
Accumulating evidence, over the years, strongly suggests the involvement of host genetic fac-
tors in the HIV-1 infection and rate of disease progression [2–4]. Therefore, intensive research 
efforts were directed toward defining the host genetic factors that may influence HIV-1 infec-
tion, virus transmission, and disease progression. Studies were focused on exploring the 
interaction between host genetic factors and the immunological and virological parameters 
[4, 5]. This will allow a better understanding of the immunopathogenesis of HIV-1 infection 
and disease outcome.
Candidate gene analysis approach was initially used to test for association of genetic vari-
ants with HIV-1 acquisition and disease rate. These variants were already known or sus-
pected to influence HIV-1 infection and rate of disease progression. Studies suggested 
several important immune response genes to be associated with HIV-1 pathogenesis [6–8]. 
This includes genes that regulate HIV-1 recognition and entry such as chemokine co-recep-
tors, human leukocyte antigens (HLA) type, T-cell receptors (TCRs), killer cell immuno-
globulin-like receptors (KIRs), and toll like receptors (TLRs). These also include genes that 
are involved in immune cell trafficking such as chemokine ligands and adhesion molecules, 
genes implicated in signaling pathways and cytokines [9]. An important host factor found 
to be strongly associated with HIV-1 disease rate was the chemokine receptor 5 (CCR5), 
the major HIV-1 co-receptor. A deletion of 32 bases from the coding region of the CCR5 
gene resulted in reduced expression of the CCR5 protein on the cell surface, rendering the 
cell completely resistant to HIV-1 infection among homozygous carriers of this deletion. 
Heterozygous carriers infected with HIV-1 were associated with delayed disease progres-
sion [10, 11]. A recent approach to identify host factors associated with AIDS progression 
is the genome-wide association studies (GWASs) [12]. This approach implies full scan of 
the human genome for additional factors without prior knowledge about their role in a 
particular disease.
A number of observational studies have found that immunological non-responders are 
at higher risk of disease progression and non-AIDS-related mortality than patients who had 
a complete response, raising a concern about the long-term effect of suboptimal immune 
response as previously reviewed in Ref. [13]. As a result, it is essential to investigate critically 
the factors that contribute to the increased risk of disease progression and predict immuno-
logic non-response during long-term cART. A number of host factors were found to be associ-
ated with immunological failure (Figure 1). Figure 1 shows a list of the most common factors 
known to affect immune recovery (i.e., CD4+ T-helper cell recovery).
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2. The chemokine receptors
Chemokine receptors are transmembrane (TM) proteins that belong to a G protein-coupled 
receptors (GPCRs), which are classified into four distinct families—CXC, CC, CX3C, and 
XC—according to the structure of their natural ligands (Figure 2a and b) [15].
All GPCR share a common molecular structure, in which they have seven TM helices and 
transmit signals from extracellular ligands to intracellular biological pathways via heterotri-
meric G proteins [16]. The structural regions required for ligand binding and receptor acti-
vation are defined for several chemokines. For example, in C-C chemokine receptor type 2 
(CCR2) which is a protein expressed on human cells such as monocytes that is encoded by 
the CCR2 gene, the N-terminus domain is required for ligand binding, but it is not efficient 
for signal transduction. However, in CCR5 receptor, an additional region called the second 
extracellular loop is crucial for ligand binding and intracellular signaling. In the case of CX3C 
chemokine receptor 1 (CX3CR1), which is a protein expressed on human cells and encoded 
by the CX3CR1 gene, residues in the N-terminus and the third extracellular loop are required 
for ligand binding and intracellular signaling [17].
Figure 1. Factors affecting immune recovery among HIV-1-infected patients on cART. Courtesy of Pinzone et al. [14]. 
HAART, highly active antiretroviral therapy; ART, antiretroviral therapy.
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Figure 2. (a) CC chemokine receptor and ligand pairing. The known chemokine receptors belonging to each of the 
chemokine families—C, CC, CXC, and CX3C—are presented around the outer ring of the wheel, with their chemokine 
ligands shown along the wheel spokes. Courtesy of White et al. [17]. (b) Schematic presentation of the key functional 
regions of chemokine receptors. Studies have identified regions important for ligand binding, receptor activation, 
and internalization, although specific sequences involved in signaling differ between different chemokine receptors. 
Courtesy of White et al. [17].
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Structurally, the GPCR can be divided into three main parts: (1) the extracellular region, con-
sisting of the N-terminus and three extracellular loops (ECL1–ECL3); (2) the transmembrane 
(TM) region, composed of seven α-helices (TM1–TM7); and (3) the intracellular region, con-
sisting of three intracellular loops (ICL1–ICL3), an intracellular amphipathic helix (H8), and 
the cellular C-terminus domain. The GPCRs possess a structural motif, which are critical for 
ligand-dependent signaling, desensitization, and receptor trafficking [18].
Another common feature of the GPCRs is the presence of aspartic acid, arginine and tyrosine 
(DRY) conserved motif at the cytoplasmic end of the third transmembrane domain, which has 
shown to be critical for signaling. The C-terminus of the GPCR receptor contains serine and 
threonine residues, which can be phosphorylated to induce recruitment of arrestin proteins. 
Beta (β) arrestin proteins have shown to be critical for receptor internalization and signal 
termination and to play an important role in the formation of a G protein-independent signal-
ing complex pathway. A redundant role was played by the chemokine and their receptors, 
for instance, the selective activation of G protein versus β-arrestin-dependent signaling path-
ways may result in differential cellular responses. Moreover, the chemokine receptors can be 
regulated at the level of phosphorylation by the recruitment of different GPCR kinases, thus 
modulating the signaling complex cascade. For example, the CCR7 binds both CCL19 and 
CCL21 leading to different cellular responses [17].
2.1. Cell signaling and chemokine receptor functions
The network signal transduction through chemokine receptors is complex and leads to dif-
ferent functional consequences including homeostatic distribution of leukocytes and their 
mobilization from the bone marrow. In addition, chemokine receptors were found to be criti-
cal during inflammation, autoimmunity, lymphoid organogenesis, angiogenesis and immune 
regulation [19]. Growing evidence suggests synergism between chemokines in leukocyte 
migration through chemokine and/or receptor heterodimerization and further contributes to 
chemokine signaling.
This leads to enhancing the local leukocyte influx, thereby amplifying the outcome of inflam-
matory responses [20]. There is little information known about the signaling pathways for 
chemokine receptors because the activated pathways depend primarily on the specific type 
of the ligand and the receptor involved. A two-step model was proposed for chemokine 
receptor binding and activation, in which the core domain of the ligand is closely associated 
with the N-terminus and extracellular loops of the chemokine receptor. In the next step, the 
N-terminus domain of the ligand penetrates the helical bundle of the receptor [20].
2.2. The CCR5 receptor
The CCR5 is a pro-inflammatory receptor that binds to chemokine (C-C motif) ligand 3 
(CCL3), CCL4, and CCL5, while CCL4 is known to be specific for CCR5 [16, 21]. CCR5 recep-
tor was first identified in 1996 [22] using molecular cloning and localized the gene to chro-
mosome 3p21 in which they suggested a potential role of this receptor in the granulocyte 
proliferation and differentiation. The CCR5 receptor is expressed on resting (memory/effec-
tor) T lymphocytes, monocytes, macrophages, and immature dendritic cells [23]. This recep-
tor was the focus for an intensive research after being identified as a co-receptor for the R5 
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strain of HIV-1 [24, 25]. HIV strain that uses the CCR5 as a co-receptor is called “CCR5 tropic” 
or “R5” tropic. The CCR5 receptor is made of 352 amino acid residues of a molecular mass 
of around 40.6 kDa. It shares around 71% sequence homology with C-C chemokine recep-
tor type 2 (CCR2), which is a protein molecule found on human cells and encoded by the 
CCR2 gene, with most of the differences are located in the extracellular and the cytoplasmic 
domains. The CCR2 gene is located close to the CCR5 gene on chromosome 3p21.
3. The CCR5 gene and HIV/AIDS
Researchers had a particular interest to some individuals who were able to remain unin-
fected with HIV-1 despite repeated exposure to the virus. Researchers were able to explain 
the cause of such phenomenon by the presence of molecular variants in the CCR5 gene that 
render the receptor inactive and further contribute to HIV-1 resistance [22, 26]. The best 
example, as mentioned above, is the deletion of the 32 base pairs in the second extracellular 
loop of CCR5 gene that results in the formation of a stop codon and the production of trun-
cated protein [27]. The truncated protein lacks the HIV-1 interaction site, and its expression 
is reduced on the cell surface, which prevents the virus from infecting a target cell. Thus, 
homozygous carriers of this deletion are completely resistant to R5 strain of HIV-1, while 
heterozygous carriers exhibit slower progression to AIDS, higher CD4+ T-helper-cell counts, 
and lower mortality rates [10].
Since the role of CCR5 receptor is vital for the primary R5 HIV-1 strains that are present early 
during HIV-1 infection, this makes the CCR5 gene one of the central candidate host genetic 
factors that could explain the variable susceptibility to HIV-1 infection [22, 26]. The CCR5Δ32 
is common in Caucasians, but it is almost rare among Asians and African populations [28, 29]. 
This clearly points out toward the importance of understanding the pattern of genetic diver-
sity and its implications for better understanding AIDS.
3.1. Polymorphisms in the CCR5 gene and rate of AIDS progression
To understand the variable HIV-1 disease course that still exists among rare carriers of the 
CCR5Δ32, studies have focused on polymorphisms in the promoter region of the CCR5 gene 
[30, 31]. In addition to the CCR5 gene variations, a mutation at the CCR2 gene has shown 
to influence HIV-1 infection. Investigators have used evolutionary-based analysis to classify 
polymorphisms at the cis-regulatory region and the Δ32 in the CCR5 gene and V64I mutation 
in the CCR2 gene into nine different CCR5 haplotypes [32]. The human haplotypes (HH) were 
defined as HHA, HHB, HHC, HHD, HHE, (HHF*1 and HHF*2), and (HHG*1 and HHG*2) 
(Figure 3) [32].
The CCR5 haplotypes may influence the HIV/AIDS disease course differentially according to 
the racial background of HIV-1-infected patients [32]. Some CCR5 haplotypes were shown to 
influence HIV-1 acquisition, early virus RNA concentration and subsequently disease pro-
gression in the absence of combination antiretroviral therapy [33], but in fact, less is known 
about the effect of these haplotypes during cART as the available information on the influence 
of the CCR5 haplotypes on AIDS treatment outcome is limited.
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We have previously reported the existence of four novel indels and two new polymorphisms 
from the Omani adult individuals [34]. The four new indels were detected out of 32 variable 
positions, −2973A/–, −2894A/–, −2827TA/–, and −2769T/–, and all were located in the 5′UTR 
of the CCR5 gene. The two new mutations, −2248G/A and +658A/G, were observed for the 
first time; the −2248G/A was detected in the Intron 1 region in one individual and +658A/G 
in the coding region of the CCR5 in another individual. In silico analysis showed that the 
novel variations in the 5’UTR could affect the transcription factor binding sites of the CCR5 
gene. Moreover, the results demonstrated that the following four minor alleles were com-
mon: CCR5-2554 T and CCR5-2086G occurred at a frequency of 49 and 46%, respectively, and 
CCR5-2459A and CCR5-2135C both existed at a frequency of 36%. These alleles had  moderate 
 heterozygosity levels indicating that they were under balancing selection. However, the 
widely known allele, CCR5Δ32, was relatively rare in the Omani sample population. Eleven 
human haplogroups (HH) were constructed, four of which were common: HHC (46%), 
HHE (20%), HHA (14%), and HHF*2 (12%).
We also performed a linkage disequilibrium (LD) pattern to classify polymorphisms on the 
CCR5 gene. Eleven haplotypes were constructed; three of them were new: HHC*A, HHF*1A, 
and HHF*2A [35]. The results of both studies indicated that the one ethnic Omani popula-
tion is genetically quite diverse when compared with other Asian populations such as Thais 
[36]. This information suggests that genetic markers can be used as predictors of the extent 
of HIV pathogenesis and immune recovery following treatment. This further indicates the 
importance of understanding the pattern of genetic diversity and its implications for a better 
understanding the human life.
Moreover, we have also investigated the possible correlation of the CCR5 haplotypes among 
Omani HIV-1-infected patients on cART with the average CD4+ T-cell count during a viremic 
period of 12 months before reaching the undetectable viral load level of <50 cells/μl. We have 
used the average CD4+ T-cell count as it provides a better understanding of the long-term effect 
Figure 3. The CCR2-CCR5 nucleotide variants and haplotypes. The main CCR2-CCR5 haplotypes are based on nine 
nucleotide variations including the V64I mutation in the CCR2 gene, the cis-regulatory region of the CCR5 promoter, 
and the Δ32 deletion in the ORF of the CCR5 gene. Linkage disequilibrium pattern between the above mentioned 
polymorphisms results in the generation of the CCR5 human haplogroup (HH) as shown in the figure. Nucleotide 
variants relative to their wild-type sequence are shown bracketed and in bold. ORF, open reading frame, and SNP, single 
nucleotide polymorphism.
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of CCR5 haplotypes compared to the use of cross-sectional values [37, 38]. In addition, we have 
investigated the possible correlation of those haplotypes with the rate of CD4+ T-cell recovery 
over the first 18 months after achieving full viral suppression following the introduction of cART.
Our results showed that the common HHC haplotype was significantly associated with higher 
mean CD4+ T-cell counts among the Omani HIV-1-infected patients (p = 0.024). The effect of 
HHC was independent and remained significant even after adjusting for the remaining CCR5 
haplotypes as possible covariates (p = 0.022). The HHC haplotype was associated with delayed 
onset of AIDS (more than 10 years) in HIV-1-infected Japanese hemophiliacs [39]. The dura-
tion from the estimated time of HIV-1 infection to CD4+ T-cell decline to <200 cells/mm3 was 
analyzed among Thai injection drug users [36]. It was found that the individuals who possess 
the HHC haplotype have a slower decline in their CD4+ T-cell counts at the late stage (around 
4 years after seroconversion) of the disease course [36]. Researchers studied the effect of CCR5 
haplotypes on the estimated time of infection to development of AIDS and time to death 
among 1151 HIV-1-infected patients that consisted of three ethnic groups, African-Americans, 
Caucasians, and Hispanics [32]. The HHC haplotype showed ethnic-specific characteristics in 
that it was associated with a delay in progression to AIDS and death among Caucasians and 
Hispanics, while it was associated with faster disease progression among African-Americans 
[32]. These investigators also found that there were differences in the effect of the same haplo-
type pairs among Caucasians and African-Americans. For example, the HHC/HHC and HHC/
HHE haplotype pairs were associated with a delay in time to death in Caucasians but not 
among African-Americans [32]. The frequency of the HHC haplotype was higher in healthy 
individuals than in HIV-1-infected patients among Indians [40], suggesting a protective role 
of this particular haplotype. On the other hand, the investigations among Chinese patients 
failed to find any association between CCR5 haplotypes and CD4+ T-cell counts [41]. However, 
in our studies, there is a significant association between HHC and CD4+ T-cell counts among 
the Omani ethnic population implying a possible protective role of HHC similar to Caucasians 
and Hispanics although the exact mechanism of this protective role is yet to be delineated.
Furthermore, we have studied the association of the average CD4+ T-cell count with immune 
recovery. The results showed that the immune responder (IR) group has a significantly higher 
level of average CD4+ T-cell count than the immune non-responder (INR) group during cART 
and before reaching undetectable viral load level (p = 0.005). In other words, individuals with 
a higher mean CD4+ T-cell count were able to better recover their CD4+ T-cell levels following 
cART compared with the individuals with a lower mean CD4+ T-cell count indicating that the 
level of average CD4+ T-cell count could be an indicator of determining the degree of immune 
recovery following successful cART, which suggests that the damage of the immune system 
during the viremic period will influence its capacity to recover upon treatment. These results 
are consistent with other findings [13, 42, 43] and support the assumption that the CD4+ T-cell 
level is an important factor that could predict immunological failure despite cART. This may 
suggest that in the INR group, the proliferation and the turnover of CD4+ T cells are impaired 
resulting in reduced production or increased destruction of CD4+ T cells.
It was noted that among the factors that could attribute to the observed phenomenon is the 
size of the thymus. It was found that HIV-1-infected patients with large thymus were able 
to better restore their CD4+ T-cell levels and have a broader immunological repertoire than 
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patients with smaller thymus. In addition, the positive association observed between the 
CD4+ T-cell counts and the immune recovery strengthens the classification method used for 
grouping the IR and INR in our studies.
To explain the variable HIV-1 disease course that still exists among rare carriers of the 
CCR5Δ32 such as Asians and African populations, studies have focused on polymorphisms 
in the promoter and/or coding region of the CCR5 gene [30]. Therefore, it was suggested that 
other polymorphisms in the CCR5 gene may influence the risk of HIV-1 transmission and 
disease progression, possibly by affecting the rate of receptor cell surface expression [30, 31, 
43]. Many novel mutations were identified within the CCR5 gene coding region in Africans 
but not among Asian or Caucasian populations. In the Asian population, a single nucleotide 
deletion in the 893 position of the CCR5 gene coding region results in the lack of the entire 
C-terminal cytoplasmic tail of the CCR5 protein, thus reducing the expression levels of CCR5 
receptors on CD4+ T cells. In addition, a rare mutation was found in the coding region of CCR5 
gene, thymine to adenine at nucleotide position 303, leading to premature termination codon 
and reduced receptor expression. This mutation was associated with increased protection 
when combined with CCR5Δ32 [31].
Several single nucleotide polymorphisms (SNPs) have been defined in the CCR5 gene pro-
moter region, the A2459G (rs1799987). Homozygous carriers of the mutant allele (−2459G) 
were found to progress slowly to AIDS more than those who carry the wild allele (−2459A) 
[30]. Another study reported a correlation between some promoter SNPs and AIDS; individu-
als lacking the −2459A and −2135C genotype may progress slowly toward AIDS/death [31].
A group of researchers identified single nucleotide polymorphisms (SNPs) in the cis-regula-
tory region of CCR5 gene at positions—−2733, −2554, −2459, −2135, −2132, −1835, CCR5Δ32—
which were grouped into seven different haplotypes (A–G), which have been shown to affect 
the HIV-1 infection and progression to AIDS [32]. The frequency distribution of haplotypes 
was different among ethnic groups, in fact some haplotypes showed variable  association 
to the disease status among different populations. For example, HHF*2 was linked to a 
delay in the progression to AIDS among African-Americans but not in Caucasians, while 
HHF*1 was associated with acceleration to AIDS among Caucasians, African-American, 
and Hispanics. HHG*2 was associated with delay in AIDS progression among Caucasians 
[32]. Understanding the pattern of genetic diversity is of great importance for understand-
ing pathogenesis of many human disorders including AIDS. Another chemokine receptor, 
CCR2, is also found to affect HIV-1 disease progression rate. A valine to isoleucine amino 
acid substitution at position 64 of the CCR2 protein is associated with delayed HIV-1 disease 
progression. In addition, the CCR2V64I mutation is tightly linked to certain SNPs in the CCR5 
cis-regulatory region [44].
To identify all the polymorphic sites that exist within the CCR5 gene as well as the CCR2V64I 
in adult individuals, we have examined the distribution of the detected variants from 
Omani adult individuals, and genomic DNA was amplified by polymerase chain reaction 
and sequenced to identify all the polymorphic sites that exist within a continuous region [of 
around 4.67 kb] of the CCR5 gene and to detect the known V64I mutation in the CCR2 gene. 
Out of 32 variable positions detected, four were new indels −2973A/–, −2894A/–, −2827TA/–, 
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and −2769T/–; all were located in the 5’UTR. Two new mutations were described for the first 
time: −2248G/A was detected in one subject in the Intron 1 region of the CCR5 gene, whereas 
+658A/G was found in the coding region. These novel variations in the 5’UTR have shown to 
exhibit potential effects in the TF binding sites by in silico analysis that merit further investi-
gation by experiments to validate our results. Moreover, we identified two novel haplotypes 
and eight known CCR2-CCR5 haplotypes; those haplotypes were found to be at different fre-
quency pattern compared to that documented worldwide. Our findings confirmed the wide 
spectrum of the genetic diversity found among populations of different ethnic groups within 
the CCR5 gene region. This will allow us to better understand the role such individuals have 
in response to HIV-1 susceptibility and AIDS progression. There is indeed a need for studying 
and understanding genetic diversity in humans in order to better understand the complicated 
pathogenesis of HIV/AIDS.
The influence of HHA, HHC, HHD, and HHE haplotypes on CCR5 receptor expression on 
B and T lymphocytes, NK cells, and monocytes among populations with either African or 
Caucasian ancestry in South Africa has been investigated [45]. In South African-Caucasians 
(SACs), the carriers of the HHC expressed CCR5 receptors at significantly higher density on 
CD56+ NK cells and CD16+ CD56+ NK cell subset than South African-Africans (SAA) who do 
not carry this haplotype [46]. This may partly explain the protective role played by the HHC 
in Caucasians but not in Africans [47]. Likewise, such impact on the density of CCR5 receptor 
expression may be the explanation of the protective role suggested in Omani patients carry-
ing HHC. However, the experimental design of the current study was different from those of 
other studies in that the effects of the haplotypes were examined during the cART, whereas 
other studies were in the absence of the cART.
The results of our studies have shown that the HHC may play a protective role among 
Omani HIV-infected patients because of its association with a high average CD4+ T-cell count. 
Therefore, the mechanism of protection to understand the involvement of CCR5 gene in AIDS 
progression among Omanis and other ethnic groups will be worth investigating.
4. Summary and future directions
Since HIV/AIDS is a major global concern, many governments implemented strategies and 
plans to control the spread of the disease and provide optimum antiretroviral treatment to 
AIDS patients. In this context, the literature review revealed that the genetic makeup of an indi-
vidual is an important factor that may influence the acquisition of the HIV and the rate of HIV/
AIDS progression. Several genes were found to be associated with HIV/AIDS, among which is 
the CCR5 gene. It is apparent that the results were inconsistent across populations regarding 
the association of these genes with the rate of progression to AIDS. Additionally, the genetic 
component of an AIDS patient on cART, whose viral replication is fully suppressed, was found 
to affect the extent of immune recovery. Limited studies were conducted and their results were 
also inconsistent in the few ethnic groups. This is because the CCR5 gene plays an important 
role in the signaling pathways that lead to the activation of T cells and T-cell survival and pro-
liferation. Additionally, many factors may affect immune recovery for patients on cART [14].
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Since the beginning of the AIDS pandemic and in the 1980s of the last century, scientists and 
clinicians were working with a disease that was not treatable at all, and the majority of patients 
died relatively quickly. In the 1990s of the last century and due to better recognition of how 
HIV spreads and to new drugs developed for treatments, AIDS became more treatable. The 
goal is now to go for a complete cure, in other words “complete viral eradication,” having the 
ability to remove the virus from the body or to suppress it to the point where it can no longer 
cause any damage to the host. This goal is reachable as the progress we are making against 
HIV/AIDS is much larger than in other comparable serious viral infections such as polio and 
smallpox [48, 49]. Currently, medications are much better than ever at treating AIDS patients, 
and our knowledge of how the immune system works against HIV/AIDS is improving.
Despite the heavy research to uncover the pathogenesis of HIV/AIDS, the whole picture of 
AIDS pathogenesis is not yet completely clear. During the infection with HIV, there is a known 
period of four to six weeks called the “window period” that we do not know much about. 
How exactly our immune system works during this critical “window period” is not completely 
understood. This was referred to as the “window of vulnerability.” This can be considered now 
as a “window of opportunity,” because in that very short period of time, there is a release of a 
huge amount of viruses and establishment of a latent HIV reservoir. It is in that short period of 
time our success or failure with vaccines as well as curing HIV/AIDS will rest. HIV reservoir 
is established literally within few days of acute infection. It has been shown that not only an 
HIV reservoir is formed early but also byproducts of CD4+ T-cell deaths increase significantly 
within days, and these cells are able to suppress the immune response to the virus. In fact, we 
have an interesting situation, an HIV reservoir that is almost immediately formed and products 
of cell death suppressing the immune response that is expected to prevent the formation of that 
reservoir. Future research should aim at reversing these processes. But we must take into con-
sideration the importance of the existence of genetic diversity in the CCR5 gene, among other 
genes, and its importance for HIV/AIDS pathogenesis [50]. Genetic diversity is important for 
the protection of humans against certain pathogens such as HIV as discussed in this chapter.
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